ArticleAnnals of medicine and surgery (2012)2025
Next-generation biodegradable cardiovascular stents: integrating biosensors and personalized drug delivery for improved outcomes.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular stents have evolved from bare metal stents to drug-eluting stents, improving outcomes in coronary interventions but posing risks of late thrombosis, inflammation, and long-term safety concerns. Biodegradable stents represent the next generation of innovation, designed to degrade into non-toxic products while minimizing inflammatory responses. Recent advances suggest further potential through the integration of biosensors and personalized drug delivery systems. Biosensors allow real-time monitoring of endothelial healing, inflammatory activity, restenosis, and local drug levels, enabling early detection of complications and timely intervention. Personalized drug release, guided by patient-specific profiles and comorbidities, can optimize therapeutic efficacy while reducing adverse effects. Although biodegradable stents face challenges related to mechanical strength, degradation timing, and implantation complexity, their combination with intelligent biosensing and adjustable drug delivery systems offers a transformative approach to reducing cardiovascular disease morbidity and mortality. The integration of these technologies may redefine future standards in interventional cardiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.